Time-cap Labs, Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Time-cap Labs, Pharmaceutical Import Records from India — 8 Products, $39.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Time-cap Labs, — Pharmaceutical Importer Profile (2026) | 8 Products, $39.1M Trade | TransData Nexus

Time-cap Labs,

Pharmaceutical Importer · United States · Analgesics & Antipyretics Focus · $39.1M Total Trade · DGFT Verified

Time-cap Labs, is a pharmaceutical importer based in United States with a total trade value of $39.1M across 8 products in 5 therapeutic categories. Based on 1,203 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Time-cap Labs, sources from 1 verified Indian supplier, with Marksans Pharma Limited accounting for 100.0% of imports.

Time-cap Labs, — Import Portfolio & Supplier Network

Time-cap Labs, import network — 8 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Time-cap Labs,?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Marksans Pharma Limited	$64.9M	2,564	100.0%

Time-cap Labs, sources from 1 verified Indian supplier across 1,581 distinct formulations. The sourcing is highly concentrated — Marksans Pharma Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Time-cap Labs, Import?

Formulation	Value	Ships
Pharmaceutical products-ibuprofen	$2.0M	49
Ibuprofen tablets USP 200 MG batch no	$2.0M	67
Ibuprofen tablets USP 200 MG batch no	$1.4M	41
Pharmaceutical products-fluoxetine	$1.1M	28
Acetaminophen er tablets USP 650 MG	$618.1K	19
Ibuprofen soft gelatin capsules 200MG	$591.6K	14
Pharmaceutical products-gabapentin	$587.5K	17
Acetamino dextrohbr & doxyl suc lfc	$583.0K	19
Pharmaceutical products-metformin	$524.3K	12
Ibuprofen soft gelatin capsules 200 MG	$522.8K	16
Acetaminophen er tablets USP 650 MG	$448.1K	16
Ibuprofen soft gelatin capsules 200MG	$440.8K	12
Ibuprofen cap 200MG (mini liquid filled)	$432.1K	10
Ibuprofen tablets USP 200MG batch no	$425.0K	16
Daytime & nighttime cold&flu mul-sytm	$396.4K	12

Import Portfolio — Top 8 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ibuprofen	Analgesics & Antipyretics	$20.7M	564	2.6%	6
2	Amino	Nutritional Supplements	$6.6M	274	2.1%	8
3	Acetaminophen	Analgesics & Antipyretics	$4.3M	131	1.8%	8
4	Naproxen	Analgesics & Antipyretics	$3.6M	90	2.7%	10
5	Fluoxetine	CNS & Psychiatric	$2.7M	62	1.1%	8
6	Famotidine	Gastrointestinal	$828.3K	65	1.5%	10
7	Guaifenesin	Respiratory & OTC	$339.4K	12	1.3%	14
8	Docusate	Gastrointestinal	$76.1K	5	0.8%	17

Time-cap Labs, imports 8 pharmaceutical products across 5 categories into United States totaling $39.1M.

Time-cap Labs, — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Time-Cap Laboratories, Inc., established in 1978, is a prominent pharmaceutical manufacturer headquartered in Farmingdale, New York. The company specializes in the production of generic pharmaceuticals, over-the-counter (OTC) medications, and nutritional supplements. Its product portfolio includes tablets, capsules, softgels, and other solid oral dosage forms, catering to a diverse range of therapeutic areas. Time-Cap Laboratories operates a state-of-the-art manufacturing facility in Farmingdale, New York, which is approved by the U.S. Food and Drug Administration (FDA). This facility produces over 50 unique products, including tablets, capsules, and pellets, and is recognized for its expertise in extended and delayed-release formulations and coating services.

In July 2015, Time-Cap Laboratories was acquired by Marksans Pharma, an Indian pharmaceutical company, through its wholly owned subsidiary Marksans Pharma Inc. This acquisition, valued at $28 million, provided Marksans Pharma with an established platform to expand its operations in the U.S. market. The acquisition enabled Marksans Pharma to enhance its manufacturing capabilities and product portfolio, particularly in the generic pharmaceutical sector.

2Distribution Network

Time-Cap Laboratories' distribution network is primarily centered in the United States, with its manufacturing facility in Farmingdale, New York, serving as the main hub for production and distribution. The company supplies its products to major retailers, chain drug stores, big-box retailers, and mail-order pharmacies across the country. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, Time-Cap Laboratories' extensive distribution network ensures widespread availability of its products throughout the U.S. market.

3Industry Role

Time-Cap Laboratories functions as a pharmaceutical manufacturer specializing in generic drugs, over-the-counter (OTC) medications, and nutritional supplements. Its role in the U.S. pharmaceutical supply chain involves the production and distribution of these products to various stakeholders, including wholesalers, retailers, and pharmacies. The company's focus on generic pharmaceuticals allows it to provide cost-effective alternatives to branded medications, thereby enhancing access to essential healthcare products for consumers.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Time-cap Labs,

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Time-Cap Laboratories' sourcing strategy exhibits a high degree of concentration, with a significant portion of its imports originating from a single supplier, Marksans Pharma Limited. This supplier concentration suggests a strategic partnership aimed at ensuring consistent product quality and supply chain efficiency. The substantial volume of imports from Marksans Pharma Limited indicates a stable and reliable relationship, which is crucial for maintaining uninterrupted product availability in the U.S. market. However, such dependency also presents potential risks, including exposure to supply chain disruptions or regulatory changes affecting the supplier. Diversifying the supplier base could mitigate these risks and enhance supply chain resilience.

2Supply Chain Resilience

Time-Cap Laboratories' supply chain resilience is closely tied to its relationship with Marksans Pharma Limited, the primary supplier of its imported pharmaceutical formulations. The company's reliance on a single supplier for a significant portion of its product line may expose it to risks associated with supply chain disruptions, such as production delays, quality control issues, or regulatory challenges faced by the supplier. To bolster supply chain resilience, Time-Cap Laboratories could consider establishing relationships with additional suppliers, thereby reducing dependency on a single source and enhancing the flexibility and robustness of its supply chain.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

The U.S. Food and Drug Administration (FDA) is the primary regulatory authority overseeing the importation and marketing of pharmaceutical products in the United States. The FDA enforces the Federal Food, Drug, and Cosmetic Act (FD&C Act), which sets forth the legal requirements for drug products, including those imported from foreign countries. For Indian pharmaceutical products, the FDA requires that manufacturers comply with its regulations, including Good Manufacturing Practice (GMP) standards, to ensure the safety, efficacy, and quality of drugs entering the U.S. market. The FDA also conducts inspections of foreign manufacturing facilities to verify compliance with these standards.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are governed by the FDA. Manufacturers and importers must register their establishments and list their drug products with the FDA. Additionally, imported drugs must comply with FDA's standards for quality, safety, and effectiveness. The FDA recognizes various GMP certifications, including those from the European Union (EU GMP), World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications are considered acceptable by the FDA, provided they meet the agency's standards. Importers must ensure that their suppliers hold valid GMP certifications recognized by the FDA to facilitate the importation process.

Time-cap Labs, — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Time-Cap Laboratories' product strategy focuses on the production of generic pharmaceuticals, over-the-counter (OTC) medications, and nutritional supplements. The company's emphasis on these therapeutic areas aligns with market demand for cost-effective alternatives to branded medications and the growing consumer interest in health and wellness products. By offering a diverse range of products, Time-Cap Laboratories aims to meet the needs of various consumer segments and maintain a competitive position in the U.S. pharmaceutical market.

2Sourcing Profile

Time-Cap Laboratories' sourcing strategy is characterized by a high degree of concentration, with a significant portion of its imported pharmaceutical formulations sourced from Marksans Pharma Limited in India. This strategic partnership allows Time-Cap Laboratories to leverage Marksans Pharma's manufacturing capabilities and product portfolio, ensuring a consistent supply of quality products. The company's focus on sourcing from a single supplier reflects a strategic choice aimed at streamlining operations and maintaining product quality.

3Market Positioning

Seller's Guide — How to Become a Supplier to Time-cap Labs,

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Time-Cap Laboratories' sourcing strategy, particularly in therapeutic areas where the company seeks to expand its product offerings. Potential suppliers must meet FDA's stringent quality and regulatory standards, including holding recognized GMP certifications and adhering to labeling requirements. By establishing relationships with additional suppliers, Time-Cap Laboratories can diversify its product portfolio and enhance supply chain resilience.

2Requirements & Qualifications

Indian exporters seeking to supply Time-Cap Laboratories and the U.S. market must obtain FDA registration and listing for their establishments and drug products. They must also hold valid GMP certifications recognized by the FDA, such as EU GMP, WHO GMP, or PIC/S certifications. Additionally, exporters must ensure compliance with FDA's quality, labeling, and serialization requirements to facilitate the importation process.

3How to Approach

Frequently Asked Questions — Time-cap Labs,

What products does Time-cap Labs, import from India?

Time-cap Labs, imports 8 pharmaceutical products across 5 categories. Top imports: Ibuprofen ($20.7M), Amino ($6.6M), Acetaminophen ($4.3M), Naproxen ($3.6M), Fluoxetine ($2.7M).

Who supplies pharmaceuticals to Time-cap Labs, from India?

Time-cap Labs, sources from 1 verified Indian suppliers. The primary supplier is Marksans Pharma Limited (100.0% of imports, $64.9M).

What is Time-cap Labs,'s total pharmaceutical import value?

Time-cap Labs,'s total pharmaceutical import value from India is $39.1M, based on 1,203 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Time-cap Labs, focus on?

Time-cap Labs, imports across 5 categories. The largest: Analgesics & Antipyretics (73.0%), Nutritional Supplements (17.0%), CNS & Psychiatric (6.8%).

Get Full Time-cap Labs, Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.